Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 6,846 matching trials from the live ClinicalTrials.gov search.
Filters: Orlando, Florida Clear all
Completed Phase 2 Interventional

A Study of ABT-751 in Patients With Renal Cell Cancer

NCT00073112
View directory record Official record
Conditions
Renal Cell Cancer
Interventions
ABT-751
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Montebello, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Oct 31, 2026, 9:15 PM EDT
Recruiting Phase 1 Interventional

A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

NCT06555419
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Nusinersen, ThecaFlex DRx System
Drug · Device
Lead sponsor
Biogen
Industry
Eligibility
3 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

NCT05274100
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
8
States / cities
Anaheim, California • Cypress, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 31, 2026, 9:15 PM EDT
Active, not recruiting Phase 3 Interventional

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

NCT04071457
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Daratumumab/rHuPH20
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2040
U.S. locations
837
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

NCT03538301
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose), Other: Placebo
Drug · Other
Lead sponsor
Nitto Denko Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • Northridge, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Vilazodone in Major Depressive Disorder

NCT01473381
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone, Placebo to citalopram, Placebo to vilazodone, Citalopram
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Oct 31, 2026, 9:15 PM EDT
Withdrawn Not applicable Interventional

Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate

NCT03589781
View directory record Official record
Conditions
Prostate Cancer
Interventions
Mikei Red Reishi Essence EX, Placebo
Dietary Supplement
Lead sponsor
Nikkei (Canada) Marketing Limited
Industry
Eligibility
50 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

NCT03066830
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
28
States / cities
Litchfield Park, Arizona • Peoria, Arizona • Greenbrae, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

NCT03291067
View directory record Official record
Conditions
Menopause Hot Flashes
Interventions
MT-8554 1mg, MT-8554 5mg, MT-8554 10mg, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
63
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Of GW679769 In Major Depressive Disorder

NCT00102492
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
356 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 31, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

NCT03955471
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Scottsdale, Arizona • Duarte, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 31, 2026, 9:15 PM EDT
Terminated Phase 1 Interventional

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

NCT05935098
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
Interventions
BGB-A3055, Tislelizumab, Chemotherapy
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Orlando, Florida • Iowa City, Iowa • Hackensack, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 31, 2026, 9:15 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia

NCT02569398
View directory record Official record
Conditions
Asymptomatic Amyloid-positive
Interventions
Atabecestat, 5 mg, Atabecestat, 25 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years to 85 Years
Enrollment
557 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment

NCT00768404
View directory record Official record
Conditions
Renal Impairment
Interventions
Topirmate and Phentermine
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
19 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2009 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 2 Interventional

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

NCT01519804
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Placebo, cisplatin/carboplatin, onartuzumab, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
34
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 31, 2026, 9:15 PM EDT
Enrolling by invitation Phase 3 Interventional

A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy

NCT07807995
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
Povetacicept
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Arvada, Colorado • Orlando, Florida • Idaho Falls, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 1Phase 2 Interventional

Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT00002577
View directory record Official record
Conditions
Lung Cancer
Interventions
radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
224
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 175 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

NCT01824875
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions
temozolomide, capecitabine
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
323
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 221 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05395481
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions
LY3849891, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Chandler, Arizona • Orange, California • Rialto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Chronic Low Back Pain

NCT04874636
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
LY3556050, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
33
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 31, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional Results available

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

NCT00326911
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
cetuximab, bevacizumab, gemcitabine
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
16
States / cities
Jonesboro, Arkansas • San Francisco, California • Stamford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

NCT00359944
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AC-3933, Sugar Pill
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
55 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
LIttle Rock, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Phase 1Phase 2 Interventional

Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin

NCT00382798
View directory record Official record
Conditions
Healthy Volunteers, Hepatitis C Virus
Interventions
RO5024048
Drug
Lead sponsor
Pharmasset
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2009 · Synced Oct 31, 2026, 9:15 PM EDT
Completed Not applicable Interventional Results available

Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion

NCT01126593
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
0.5% bupivacaine, Normal Saline
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years to 90 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2014 · Synced Oct 31, 2026, 9:15 PM EDT